Looking for technology to develop a medical device for non-invasive diagnosis of prodromal Alzheimer’s
A Dutch company offers a new way of looking at Alzheimer’s development by applying (epi-)genetics-based knowledge to factors that epidemiologically and/or experimentally have been linked to Alzheimer's development
Publié le
21 octobre 2020
Date de clôture
28 février 2021
Lieu(x)
PAYS-BAS
Marché(s) cible(s)
Dispositifs médicaux
Type de collaboration recherchée
Partenaire
For project second phase, the company is looking for a partner experienced in biosensor/like technology to develop a simple inexpensive device for screening, diagnosis and efficacy follow-up during drug development, within the frame of a joint venture or a license agreement.
Partner type: (preferentially Biotech company) experienced in biosensor, biosensor/like or equivalent innovative technology allowing for detection of a microRNA profile in human blood, plasma or serum for diagnosis based on a specific algorithm.
The partner is expected to develop a biosensor, biosensor/like or equivalent allowing for detection of a microRNA profile at levels of pico tot femtogram’s per millilitre in human blood, plasma or serum for diagnosis based on a specific algorithm.
Certification standards (ISO 13485) and compliance with Directive 98/79/EU under the Commission Implementing Decision (EU) 2020/439 are requested
If you are interested, ask to be put in touch with an advisor who can tell you more about this business opportunity and how to position yourself.